Antimicrobial resistance to linezolid
Antimicrobial resistance to linezolid
复制标题
DOI：
10.1086/423841
复制
发表时间：
2004-10-01
影响因子：
11.8
通讯作者：
Gold, HS
中科院分区：
文献类型：
--
作者：
Meka, VG;Gold, HS
对利奈唑胺的获得性耐药性是第一个被批准的恶唑烷酮类药物，已在实验室实验中选择，并在革兰氏阳性球菌的临床分离株中观察到。这种耐药性通常与编码23S核糖体RNA的基因拷贝数不同的单核苷酸变化有关。在目前对标准抗生素的耐药性日益普遍的环境下，利奈唑胺是一种重要的药物，因为它对一些临床上有意义的革兰氏阳性球菌具有活性，包括耐多药葡萄球菌和肠球菌。尽管对利奈唑胺的耐药性仍然不常见，但临床分离株的耐药性的发展应促使对该药物的敏感性测试给予更多的关注，并应考虑该药物的治疗使用。
Acquired resistance to linezolid, the first approved oxazolidinone, has been selected in laboratory experiments and has been observed in clinical isolates of gram- positive cocci. This resistance has typically been associated with single- nucleotide changes in varying numbers of copies of the genes encoding 23S ribosomal RNA. In the current environment of increasingly prevalent resistance to standard antibiotics, linezolid is an important drug because of its activity against a number of clinically significant gram- positive cocci, including multidrug- resistant staphylococci and enterococci. Although resistance to linezolid remains uncommon, the development of resistance by clinical isolates should prompt increased attention to susceptibility testing for this agent and should be taken into account in consideration of the therapeutic use of this drug.